<DOC>
	<DOCNO>NCT01788566</DOCNO>
	<brief_summary>The purpose study see participant late stage lung cancer gemcitabine-cisplatin chemotherapy plus necitumumab . The study also see safe drug combination see long medicine stay body . The study last approximately 2 year .</brief_summary>
	<brief_title>A Study Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab First-Line Treatment Participants With Squamous Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm squamous Nonsmall Cell Lung Cancer ( NSCLC ) Stage IV disease time study entry base American Joint Committee Cancer 7th edition Measurable disease time study entry define Response Evaluation Criteria Solid Tumors ( RECIST ) , Version 1.1 Required performance status ( PS ) 01 Nonsquamous NSCLC Prior anticancer therapy monoclonal antibody , signal transduction inhibitor , therapy target epidermal growth factor receptor ( EGFR ) , vascular endothelial growth factor ( VEGF ) , VEGF receptor Previous chemotherapy NSCLC Major surgery receive investigational therapy 4 week prior study enrollment Chest irradiation within 12 week prior randomization ( except palliative irradiation bone lesion , allow ) Brain metastasis symptomatic require ongoing treatment steroid anticonvulsant ( participant undergone previous radiotherapy brain metastasis , nonsymptomatic long require treatment steroid anticonvulsant , eligible )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>